Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
EC grants conditional marketing authorization based on the EFFISAYIL trial
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Anandiben Patel, Governor, Uttar Pradesh will inaugurate the two-day celebrations
Subscribe To Our Newsletter & Stay Updated
